Recent setback in some of Takeda’s clinical trials has led to downward revision of profit guidance. Takeda remains focused on pipeline development and newly launched drugs show strong potential
Boomeranged on Thu, 9 Nov 2023 17:22
As we have highlighted, Takeda continues to make good progress with its development pipeline where the company has received FDA approval for Fruquintinib/Fruzaqla (acquired from Hutchmed) yesterday. At the same time, the company also announced that its Psoriasis drug TAK-279 (acquired from Nimbus Therapeutics) has met primary endpoint in Phase IIb trial and will initiate phase III trials.
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.